Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Dr Reddys Laboratories Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (303)
ARTG (234)
Prescription medicine registration (15)

Date

2024 (31)
2023 (161)
2022 (28)
2021 (55)
2020 (48)
2019 (26)
2018 (52)
2017 (35)
2016 (78)
2014 (2)
2013 (9)
2012 (16)
2011 (2)
2010 (9)

Results for "[search-keyword]"

Search

Sponsor content

552 result(s) found, displaying 131 to 140

DOCETAXEL-DRLA docetaxel 20 mg/1 ml Concentrated Solution for Infusion vial Cancelled under Section 30(1)(c) of the Act

23 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
DOTAX docetaxel 80 mg/4 ml Concentrated Solution for Infusion vial Cancelled under Section 30(1)(c) of the Act

23 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
DOCETERE docetaxel 20 mg/1 ml Concentrated Solution for Infusion vial Cancelled under Section 30(1)(c) of the Act

23 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
DOCETAXEL-RZ docetaxel 80 mg/4 ml Concentrated Solution for Infusion vial Cancelled under Section 30(1)(c) of the Act

23 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
DOCETAXEL-DRLA docetaxel 80 mg/4 ml Concentrated Solution for Infusion vial Cancelled under Section 30(1)(c) of the Act

23 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
ESCITALOPRAM-DRLA escitalopram (as oxalate) 20mg tablet bottle Cancelled under Section 30(1)(c) of the Act

23 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
ESCITALOPRAM-DRLA escitalopram (as oxalate) 10mg tablet bottle Cancelled under Section 30(1)(c) of the Act

23 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
FINPRO finasteride 5 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

23 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
GEMCITABINE DRLA gemcitabine (as hydrochloride) 1 g powder for injection vial Cancelled under Section 30(1)(c) of the Act

23 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
GEMICOR gemcitabine (as hydrochloride) 200 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

23 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd

Pages

First page
Previous page
…
Page 10
Page 11
Page 12
Page 13
Current page 14
Page 15
Page 16
Page 17
Page 18
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.